Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
MHC-Restricted Cytotoxic T Cells: Studies on the Biological Role of Polymorphic Major Transplantation Antigens Determining T-Cell Restriction-Specificity, Function, and Responsiveness
1979 StandoutNobel
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Gastric cancer
2016 Standout
Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
1999
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
2007
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
1998
Effect of cisplatin upon expression of in vivo immune tumor resistance
1993
Preclinical and Clinical Pharmacology of Vinca Alkaloids
1992
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs
1993
Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles
2004
Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial
2000
Phase I study of oxaliplatin in patients with advanced cancer
1990
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
1997
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
1996
The Risk–Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava
2002 Standout
Drug development from marine natural products
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
1995
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Phytotherapy in the treatment of benign prostatic hyperplasia: an update
1999
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects
2005
Anti-proliferative activity and mechanism of action of titanocene dichloride
1998
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
2004 StandoutNobel
New Cisplatin Analogues in Development
1993
Molecular mechanisms of cisplatin resistance
2011 Standout
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
1992
Macrophage and T Cell Dynamics during the Development and Disintegration of Mycobacterial Granulomas
2008
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug
2005
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study
2010
Apoptosis in Young Rats with Adriamycin-Induced Cardiomyopathy—Comparison with Pirarubicin, a New Anthracycline Derivative
2002
Cellular processing of platinum anticancer drugs
2005 Standout
Circadian clock control of the cellular response to DNA damage
2010 StandoutNobel
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
1990
Photodynamic therapy and anti-tumour immunity
2006 Standout
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
Congestive heart failure in patients treated with doxorubicin
2003 Standout
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998
The Cucurbit[n]uril Family
2005 Standout
Tumour-inhibiting platinum complexes—state of the art and future perspectives
2003
Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data
1989
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Ongoing and unsaid on oxaliplatin: the hope
1998
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells
2005 StandoutNobel
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
2007
Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA
1998
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
1993
New platinum antitumor complexes
1993
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Toll-Like Receptors
2003 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Current Developments in Cancer Vaccines and Cellular Immunotherapy
2003
CYTOTOXICITY AFTER B.C.G. INFECTION
1974
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
2009 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Organometallic Anticancer Compounds
2010 Standout
Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal
1996
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
2000
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Current status of trans-platinum compounds in cancer therapy
2001
Additions to Metal-Activated Organonitriles
2002 Standout
Cellular and molecular pharmacology of oxaliplatin.
2002
Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer
1977 Standout
Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C
2004
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma
1978
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
1997
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)
1994
Chemoimmunotherapy of Disseminated Malignant Melanoma with Dimethyl Triazeno Imidazole Carboxamide and Bacillus Calmette-Guérin
1974
The Anthracycline Antineoplastic Drugs
1981 Standout
Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase.
1983
Cell-Mediated Immune Responses in Tuberculosis
2009 Standout
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
1995
Maturation of Human Dendritic Cells by Cell Wall Skeleton ofMycobacterium bovisBacillus Calmette-Guerin: Involvement of Toll-Like Receptors
2000
The current status of new platinum analogs.
1992
Works of C Bourut being referenced
A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy
1995
Experimental Screening for “Systemic Adjuvants of Immunity” Applicable in Cancer Immunotherapy
1974
Effectiveness of Murine Leukemia Chemotherapy According to the Immune State: Reconsideration of Correlations Between Chemotherapy, Tumour Cell Killing, and Survival Time
1977
Antitumor activity of l-OHP in mice
1985
Experimental in vivo cross-resistance of vinca alkaloid drugs
1981
Histologic reactions of the thymus, spleen, liver and lymph nodes to intravenous and subcutaneous BCG injections.
1975
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
1989
Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.
1979
Effectiveness of murine leukemia chemotherapy according to the immune state
1977
Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin.
1979
Experimental antitumor activity of 5′-nor-anhydrovinblastine navelbine
1984
BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
1973